Article
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
American heart journal - 1 May 2017
Ho Carolyn Y, McMurray John J V, Cirino Allison L, Colan Steven D, Day Sharlene M, Desai Akshay S, Lipshultz Steven E, MacRae Calum A, Shi Ling, Solomon Scott D, Orav E John, Braunwald Eugene
Abstract excerpt
Hypertrophic cardiomyopathy (HCM) is often caused by sarcomere gene mutations, resulting in left ventricular hypertrophy (LVH), myocardial fibrosis, and increased risk of sudden cardiac death and heart failure. Studies in mouse models of sarcomeric HCM demonstrated that early treatment with an angiotensin receptor blocker (ARB) reduced development of LVH and fibrosis. In contrast, prior human studies using ARBs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.